SIMON MELNICK: Open Payments
NPI 1093754780 · SOMERSET, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$803 in 33 payments from 10 companies in 2025. Trend: 2023 $1,116 · 2024 $1,180 · 2025 $803
Food & beverage: $803
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 18 | $496 |
| Lilly USA, LLC | 4 | $79 |
| Novo Nordisk Inc | 3 | $62 |
| Viatris Specialty LLC | 2 | $37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $26 |
| Abbott Laboratories | 1 | $23 |
| SCPHARMACEUTICALS INC. | 1 | $22 |
| Corcept Therapeutics | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $20 |
| Amgen Inc. | 1 | $16 |
Products named: FARXIGA, AIRSUPRA, BREZTRI, MOUNJARO, Ozempic, YUPELRI, JARDIANCE, FREESTYLE LIBRE 3.
Industry payments across MA — which companies pay providers there.
